Cantor Fitzgerald assumed coverage of Compass Pathways (CMPS) with an Overweight rating and $12 price target This is an important year for the psychedelic space in general with multiple randomized clinical trial data readouts, the analyst tells investors in a research note. The firm thinks there is potentially more upside to shares than options imply.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Positive Outlook for COMPASS Pathways Amid Promising Clinical Developments and Strong Financial Position
- Positive Outlook for COMPASS Pathways: Buy Rating Backed by Promising Developments in Mental Health Treatments and Strong Financial Position
- Buy Rating Reiterated for COMPASS Pathways: Promising Phase 3 Trials and Strong Financial Position Highlighted
- Compass Pathways Reports Improved Quarterly Results
- Compass Pathways’ Earnings Call Highlights Progress and Challenges